Google
Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations
Shares of Oric Pharmaceuticals sank 40% Wednesday after the cancer biotech reported study results that were positive--but not positive enough for Wall Street. In an early-stage trial, Oric’s prostate-cancer drug candidate showed signs of a “best in disease” profile, the company said.
Continue Reading
